Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.

BACKGROUND The N-acetyltransferase 2 (NAT2) enzyme detoxifies aromatic amines, an important class of carcinogens in tobacco smoke. Slow acetylation phenotype individuals have reduced detoxification capacity compared with those with a rapid/intermediate phenotype. Analysis of the Spanish Bladder Cancer Study found an odds ratio (OR) for slow acetylators relative to rapid/intermediate acetylators of 0.9 in never-smokers and 1.6 in ever-smokers, a 1.8-fold enhancement in smokers. Evidence indicates that acetylation is an exposure-dependent process, and thus the magnitude of the interaction may also depend on exposure level. METHODS We extend a comprehensive three-parameter linear-exponential model for the excess odds ratio (EOR) for smoking to include effects of NAT2 status, and reanalyse smoking and NAT2 status for the bladder cancer data. RESULTS We show that variations in smoking risk with NAT2 status result from interactions with smoking intensity (cigarettes per day) and not total pack-years of exposure. In addition, the relative increase in smoking risk in NAT2 slo acetylators increases with smoking intensity. CONCLUSIONS Analyses reveal an enhanced effect for smoking intensity and bladder cancer in NAT2 slow acetylators which increases with intensity.

[1]  Neil E. Caporaso,et al.  Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity , 2006, Cancer Epidemiology Biomarkers & Prevention.

[2]  M. Green,et al.  Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[3]  G. Talaska,et al.  High-performance liquid chromatography method for determination of N-glucuronidation of 4-aminobiphenyl by mouse, rat, and human liver microsomes. , 2005, Analytical biochemistry.

[4]  S. R. Babu,et al.  Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. , 1996, Biochemical pharmacology.

[5]  M. Kogevinas,et al.  Levelling-off of the risk of lung and bladder cancer in heavy smokers: an analysis based on multicentric case-control studies and a metabolic interpretation. , 2000, Mutation research.

[6]  H. Engelhardt High performance liquid chromatography , 1997 .

[7]  Núria Malats,et al.  Smoking and Bladder Cancer in Spain: Effects of Tobacco Type, Timing, Environmental Tobacco Smoke, and Gender , 2006, Cancer Epidemiology Biomarkers & Prevention.

[8]  P. Vineis,et al.  Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  Dong Liang,et al.  Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. , 2005, Mutation research.

[10]  Steven R. Tannenbaum,et al.  Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens , 1994, Nature.

[11]  N. Malats,et al.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses , 2005, The Lancet.